AU2014385320B2 - E1E2 HCV vaccines and methods of use - Google Patents

E1E2 HCV vaccines and methods of use Download PDF

Info

Publication number
AU2014385320B2
AU2014385320B2 AU2014385320A AU2014385320A AU2014385320B2 AU 2014385320 B2 AU2014385320 B2 AU 2014385320B2 AU 2014385320 A AU2014385320 A AU 2014385320A AU 2014385320 A AU2014385320 A AU 2014385320A AU 2014385320 B2 AU2014385320 B2 AU 2014385320B2
Authority
AU
Australia
Prior art keywords
polypeptide
hcv
genotype
hcv genotype
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014385320A
Other languages
English (en)
Other versions
AU2014385320A1 (en
Inventor
Darren HOCKMAN
Michael Houghton
John L. Law
Michael Logan
D. Lorne Tyrrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Publication of AU2014385320A1 publication Critical patent/AU2014385320A1/en
Application granted granted Critical
Publication of AU2014385320B2 publication Critical patent/AU2014385320B2/en
Priority to AU2020200216A priority Critical patent/AU2020200216A1/en
Priority to AU2022200747A priority patent/AU2022200747A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014385320A 2013-05-15 2014-05-15 E1E2 HCV vaccines and methods of use Active AU2014385320B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020200216A AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use
AU2022200747A AU2022200747A1 (en) 2013-05-15 2022-02-04 E1E2 HCV vaccines and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US61/823,712 2013-05-15
US201361887229P 2013-10-04 2013-10-04
US61/887,229 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200216A Division AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use

Publications (2)

Publication Number Publication Date
AU2014385320A1 AU2014385320A1 (en) 2015-11-12
AU2014385320B2 true AU2014385320B2 (en) 2019-10-10

Family

ID=54054625

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014385320A Active AU2014385320B2 (en) 2013-05-15 2014-05-15 E1E2 HCV vaccines and methods of use
AU2020200216A Abandoned AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use
AU2022200747A Abandoned AU2022200747A1 (en) 2013-05-15 2022-02-04 E1E2 HCV vaccines and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020200216A Abandoned AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use
AU2022200747A Abandoned AU2022200747A1 (en) 2013-05-15 2022-02-04 E1E2 HCV vaccines and methods of use

Country Status (8)

Country Link
US (3) US20210145963A9 (enExample)
EP (2) EP2996718B1 (enExample)
JP (5) JP2016520077A (enExample)
CN (2) CN112999344A (enExample)
AU (3) AU2014385320B2 (enExample)
CA (1) CA2909586C (enExample)
CL (1) CL2015003333A1 (enExample)
WO (1) WO2015132619A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000313A1 (en) * 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
AU2017332854B2 (en) * 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
EP3525817A4 (en) * 2016-10-11 2020-09-16 The Governors of the University of Alberta HEPATITIS C VIRUS-BASED IMMUNOGENIC COMPOSITIONS INCLUDING AS ADJUSTING A CYCLIC DINULEOTIDE OR ARCHAEOSOME AND THEIR METHODS OF USE
EP3765075A4 (en) * 2018-03-16 2021-12-08 The Governors of the University of Alberta HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF
WO2025222304A1 (en) * 2024-04-26 2025-10-30 The Governors Of The University Of Alberta Hcv genotype3 e2 envelope protein for neutralizing infectivity of hcv strains

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP4458556B2 (ja) 1997-05-06 2010-04-28 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃ型肝炎のｅ２短縮型ポリペプチドの細胞内生成
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
CN1636015A (zh) * 2001-06-29 2005-07-06 希龙公司 Hcv e1e2疫苗组合物
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GROLLO LARA ET AL, ANTIVIRAL THERAPY- AN OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY FOR ANTIVIRAL RESEARCH, MTM PUBLICATIONS, LONDON, GB, (2006-01-01), vol. 11, no. 8, ISSN 1359-6535, pages 1005 - 1014 *

Also Published As

Publication number Publication date
US20210145963A9 (en) 2021-05-20
AU2020200216A1 (en) 2020-02-06
JP2024156917A (ja) 2024-11-06
US20160067332A1 (en) 2016-03-10
WO2015132619A1 (en) 2015-09-11
AU2022200747A1 (en) 2022-02-24
CL2015003333A1 (es) 2016-09-30
JP2021059596A (ja) 2021-04-15
AU2014385320A1 (en) 2015-11-12
EP2996718A4 (en) 2017-06-21
CN105263517B (zh) 2021-03-26
CN105263517A (zh) 2016-01-20
CA2909586A1 (en) 2015-09-11
CA2909586C (en) 2021-08-31
US20230098265A1 (en) 2023-03-30
EP3689375A1 (en) 2020-08-05
CN112999344A (zh) 2021-06-22
JP2016520077A (ja) 2016-07-11
HK1216395A1 (en) 2016-11-11
US20240316186A1 (en) 2024-09-26
EP2996718A1 (en) 2016-03-23
JP2022172244A (ja) 2022-11-15
EP2996718B1 (en) 2020-01-15
JP2019142962A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
US20240316186A1 (en) E1e2 hcv vaccines and methods of use
US12202859B2 (en) Hepatitis c virus E1/E2 heterodimers and methods of producing same
US20230310590A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
AU2017332854B2 (en) Hepatitis C virus immunogenic compositions and methods of use thereof
WO2014060851A2 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HK1216395B (en) E1e2 hcv vaccines and methods of use
HK40120034A (en) Hepatitis c virus e1/e2 heterodimers and methods of producing same
HK1255379B (en) Hepatitis c virus immunogenic compositions and methods of use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HOUGHTON, MICHAEL; HOCKMAN, DARREN; LAW, JOHN L.; LOGAN, MICHAEL AND TYRRELL, D. LORNE

FGA Letters patent sealed or granted (standard patent)